TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Prophase Labs ( (PRPH) ) is now available.
On November 19, 2025, ProPhase Labs announced its strategic initiatives, including M&A discussions and the commercialization of the BE-Smart™ Esophageal Cancer Test following a landmark study. The company is also pursuing a $50 million collection initiative through Crown Medical, which has been appointed as Special Counsel to expedite litigation against insurance carriers. These efforts aim to unlock significant value for ProPhase, which it believes is not reflected in its current share price.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
Spark’s Take on PRPH Stock
According to Spark, TipRanks’ AI Analyst, PRPH is a Neutral.
Prophase Labs’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and negative profitability. The technical analysis further indicates bearish momentum, while valuation metrics highlight significant concerns with a negative P/E ratio. Although the earnings call provided some optimism with potential cash recovery and new ventures, the current financial challenges and market sentiment weigh heavily on the stock’s outlook.
To see Spark’s full report on PRPH stock, click here.
More about Prophase Labs
ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer product company.
Average Trading Volume: 1,902,162
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11M
For a thorough assessment of PRPH stock, go to TipRanks’ Stock Analysis page.